| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.02 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.02 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.02 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.02 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.35 | 0.02 |